Generated by AI
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release-activated calcium (CRAC) channels for serious inflammatory, immunologic, and cardiopulmonary diseases. The company’s lead candidate, Auxora, is an intravenous small-molecule CRAC channel inhibitor being evaluated in multiple settings, including acute pancreatitis, acute kidney injury, and other severe inflammatory conditions. CalciMedica also develops an oral CRAC channel inhibitor program aimed at chronic inflammatory and immunologic diseases. Its current work centers on drug discovery and clinical development for conditions where inflammation and direct cellular injury drive high unmet medical need. Based in La Jolla, California, CalciMedica plays a specialized role in the biotechnology market by advancing a differentiated calcium-channel inhibition platform for acute and chronic disease areas.
Website505 Coast Boulevard South
La Jolla, CA, 92037
United States
The latest articles about CALC.
CalciMedica Inc. (CALC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Detailed price information for Calcimedica Inc (CALC-Q) from The Globe and Mail including charting and trades.
Detailed price information for Calcimedica Inc (CALC-Q) from The Globe and Mail including charting and trades.
Summary of Nov 12's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Detailed price information for Calcimedica Inc (CALC-Q) from The Globe and Mail including charting and trades.
Summary of Jun 28's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about CALC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.